Clinical Practice ManagementTransition From Intravenous to Subcutaneous Treprostinil in a Pediatric Patient With Pulmonary HypertensionRockwell, Sarah J. PharmD*; Miller, Joette Amundaray PharmD†; Brown, Brian K. PharmD‡; Kiskaddon, Amy PharmD‡; Gilliland, Frankie DNP, CPNP, AC/PC§; Freire, Grace MD∥; Mauriello, Daniel MD∥Author Information *Department of Pharmacy, Moffitt Cancer Center, Tampa Departments of ‡Pharmacy ∥Cardiology, Johns Hopkins All Children’s Hospital §Heart Institute, Johns Hopkins All Children’s Hospital, St. Petersburg, FL †Department of Pharmacy, University of Illinois at Chicago, Chicago, IL Of note, treprostinil and tadalafil are not FDA approved for pediatric pulmonary hypertension, but the literature supports their use in this patient population for pulmonary hypertension. Disclosure: The authors declare that they have no conflicts of interest. Address correspondence to: Amy Kiskaddon, PharmD, Department of Pharmacy, Johns Hopkins All Children’s Hospital, 501 6th Avenue South, St. Petersburg, FL 33701. E-mail: email@example.com. Clinical Pulmonary Medicine: March 2020 - Volume 27 - Issue 2 - p 43-47 doi: 10.1097/CPM.0000000000000355 Buy Metrics Abstract Pulmonary hypertension (PH) causes significant morbidity and mortality in children, and, while the treatment strategies for PH in adults are well studied and developed, few data exist for pediatric patients. In adult patients, successful transitions from intravenous (IV) epoprostenol to subcutaneous (SC) treprostinil are reported, but this information is limited for pediatric patients. Furthermore, while there are reports of SC to IV treprostinil in adults, there are no reports of the transition from IV to SC treprostinil. This case report recounts a successful transition from IV treprostinil to SC treprostinil in a pediatric patient with WHO Class 3, PH, secondary to interstitial lung disease. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.